Kenzo Kosuda
Direttore Finanziario/CFO presso REGiMMUNE Corp.
Posizioni attive di Kenzo Kosuda
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
REGiMMUNE Corp.
 REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Direttore/Membro del Consiglio | 01/01/2013 | - |
| Direttore Finanziario/CFO | 01/01/2013 | - |
Storia della carriera di Kenzo Kosuda
Formazione di Kenzo Kosuda
| Keio University | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Giappone | 3 |
Posizioni
| Director/Board Member | 1 |
| Director of Finance/CFO | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 2 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
REGiMMUNE Corp.
REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Health Technology |
- Borsa valori
- Insiders
- Kenzo Kosuda
- Esperienza
